| ID |
Description |
GeneRatio |
BgRatio |
pvalue |
p.adjust |
qvalue |
geneID |
Count |
| hsa05417 |
Lipid and atherosclerosis |
21/47 |
216/8859 |
3.64E-22 |
7.64E-20 |
1.95E-20 |
TNF/IL6/AKT1/SRC/MMP9/CASP3/MAPK3/MAPK1/RHOA/PIK3CA/HRAS/JAK2/CCL5/MAPK8/MAPK14/CASP1/CASP8/NOS3/MMP3/MMP1/SELE |
21 |
| hsa04625 |
C-type lectin receptor signaling pathway |
17/47 |
105/8859 |
9.58E-22 |
1.01E-19 |
2.57E-20 |
TNF/IL6/AKT1/SRC/MAPK3/PTGS2/STAT1/MAPK1/RHOA/PIK3CA/HRAS/MDM2/MAPK8/MAPK14/SYK/CASP1/CASP8 |
17 |
| hsa05205 |
Proteoglycans in cancer |
20/47 |
204/8859 |
3.90E-21 |
2.73E-19 |
6.97E-20 |
TNF/AKT1/EGFR/SRC/MMP9/CASP3/MAPK3/IGF1/ESR1/KDR/MAPK1/RHOA/PIK3CA/HRAS/ITGB1/MDM2/HGF/IGF1R/MAPK14/PLAU |
20 |
| hsa01521 |
EGFR tyrosine kinase inhibitor resistance |
14/47 |
80/8859 |
1.96E-18 |
9.76E-17 |
2.49E-17 |
IL6/AKT1/EGFR/SRC/MAPK3/IGF1/KDR/MAPK1/PIK3CA/HRAS/JAK2/HGF/IGF1R/JAK1 |
14 |
| hsa05161 |
Hepatitis B |
17/47 |
163/8859 |
2.32E-18 |
9.76E-17 |
2.49E-17 |
TNF/IL6/AKT1/SRC/MMP9/CASP3/MAPK3/STAT1/MAPK1/PIK3CA/HRAS/JAK2/MAPK8/MAPK14/CASP8/CDK2/JAK1 |
17 |
| hsa04668 |
TNF signaling pathway |
15/47 |
119/8859 |
1.78E-17 |
6.22E-16 |
1.59E-16 |
TNF/IL6/AKT1/MMP9/CASP3/MAPK3/PTGS2/MAPK1/PIK3CA/CCL5/MAPK8/MAPK14/CASP8/MMP3/SELE |
15 |
| hsa05215 |
Prostate cancer |
14/47 |
98/8859 |
3.99E-17 |
1.20E-15 |
3.06E-16 |
AKT1/EGFR/MMP9/MAPK3/IGF1/MAPK1/PIK3CA/HRAS/MDM2/IGF1R/MMP3/CDK2/AR/PLAU |
14 |
| hsa01522 |
Endocrine resistance |
14/47 |
99/8859 |
4.63E-17 |
1.22E-15 |
3.11E-16 |
AKT1/EGFR/SRC/MMP9/MAPK3/IGF1/ESR1/MAPK1/PIK3CA/HRAS/MDM2/MAPK8/IGF1R/MAPK14 |
14 |
| hsa04933 |
AGE-RAGE signaling pathway in diabetic complications |
14/47 |
101/8859 |
6.21E-17 |
1.45E-15 |
3.70E-16 |
TNF/IL6/AKT1/CASP3/MAPK3/STAT1/MAPK1/PIK3CA/HRAS/JAK2/MAPK8/MAPK14/NOS3/SELE |
14 |
| hsa04151 |
PI3K-Akt signaling pathway |
20/47 |
362/8859 |
3.57E-16 |
7.50E-15 |
1.92E-15 |
IL6/AKT1/EGFR/MAPK3/IGF1/KDR/MAPK1/PIK3CA/KIT/HRAS/JAK2/ITGB1/MDM2/HGF/IGF1R/SYK/NOS3/CDK2/FLT1/JAK1 |
20 |
| hsa05163 |
Human cytomegalovirus infection |
17/47 |
226/8859 |
6.26E-16 |
1.20E-14 |
3.06E-15 |
TNF/IL6/AKT1/EGFR/SRC/CASP3/MAPK3/PTGS2/MAPK1/RHOA/PIK3CA/HRAS/CCL5/MDM2/MAPK14/CASP8/JAK1 |
17 |
| hsa05167 |
Kaposi sarcoma-associated herpesvirus infection |
16/47 |
196/8859 |
1.47E-15 |
2.57E-14 |
6.57E-15 |
IL6/AKT1/SRC/CASP3/MAPK3/PTGS2/STAT1/MAPK1/PIK3CA/HRAS/JAK2/MAPK8/MAPK14/SYK/CASP8/JAK1 |
16 |
| hsa04068 |
FoxO signaling pathway |
14/47 |
133/8859 |
3.31E-15 |
5.34E-14 |
1.37E-14 |
IL6/AKT1/EGFR/MAPK3/IGF1/MAPK1/PIK3CA/HRAS/MDM2/MAPK8/SIRT1/IGF1R/MAPK14/CDK2 |
14 |
| hsa04015 |
Rap1 signaling pathway |
16/47 |
212/8859 |
5.13E-15 |
7.70E-14 |
1.97E-14 |
AKT1/EGFR/SRC/MAPK3/IGF1/KDR/MAPK1/RHOA/PIK3CA/KIT/HRAS/ITGB1/HGF/IGF1R/MAPK14/FLT1 |
16 |
| hsa05152 |
Tuberculosis |
15/47 |
182/8859 |
1.16E-14 |
1.63E-13 |
4.16E-14 |
TNF/IL6/AKT1/SRC/CASP3/MAPK3/STAT1/MAPK1/RHOA/JAK2/MAPK8/MAPK14/SYK/CASP8/JAK1 |
15 |
| hsa04657 |
IL-17 signaling pathway |
12/47 |
95/8859 |
4.35E-14 |
5.71E-13 |
1.46E-13 |
TNF/IL6/MMP9/CASP3/MAPK3/PTGS2/MAPK1/MAPK8/MAPK14/CASP8/MMP3/MMP1 |
12 |
| hsa04917 |
Prolactin signaling pathway |
11/47 |
71/8859 |
5.42E-14 |
6.70E-13 |
1.71E-13 |
AKT1/SRC/MAPK3/ESR1/STAT1/MAPK1/PIK3CA/HRAS/JAK2/MAPK8/MAPK14 |
11 |
| hsa04510 |
Focal adhesion |
15/47 |
203/8859 |
5.93E-14 |
6.91E-13 |
1.77E-13 |
AKT1/EGFR/SRC/MAPK3/IGF1/KDR/MAPK1/RHOA/PIK3CA/HRAS/ITGB1/HGF/MAPK8/IGF1R/FLT1 |
15 |
| hsa05135 |
Yersinia infection |
13/47 |
138/8859 |
1.61E-13 |
1.78E-12 |
4.54E-13 |
TNF/IL6/AKT1/SRC/MAPK3/MAPK1/RHOA/PIK3CA/ITGB1/MAPK8/MAPK14/CASP1/LCK |
13 |
| hsa04066 |
HIF-1 signaling pathway |
12/47 |
109/8859 |
2.37E-13 |
2.37E-12 |
6.05E-13 |
IL6/GAPDH/AKT1/EGFR/MAPK3/IGF1/MAPK1/PIK3CA/IGF1R/HMOX1/NOS3/FLT1 |
12 |
| hsa04620 |
Toll-like receptor signaling pathway |
12/47 |
109/8859 |
2.37E-13 |
2.37E-12 |
6.05E-13 |
TNF/IL6/AKT1/MAPK3/STAT1/MAPK1/PIK3CA/CCL5/MAPK8/MAPK14/CASP8/JAK1 |
12 |
| hsa05145 |
Toxoplasmosis |
12/47 |
112/8859 |
3.30E-13 |
3.15E-12 |
8.05E-13 |
TNF/AKT1/CASP3/MAPK3/STAT1/MAPK1/JAK2/ITGB1/MAPK8/MAPK14/CASP8/JAK1 |
12 |
| hsa04370 |
VEGF signaling pathway |
10/47 |
60/8859 |
3.95E-13 |
3.61E-12 |
9.22E-13 |
AKT1/SRC/MAPK3/PTGS2/KDR/MAPK1/PIK3CA/HRAS/MAPK14/NOS3 |
10 |
| hsa05171 |
Coronavirus disease - COVID-19 |
15/47 |
238/8859 |
6.18E-13 |
5.41E-12 |
1.38E-12 |
TNF/IL6/EGFR/MAPK3/STAT1/MAPK1/PIK3CA/MAPK8/MAPK14/SYK/CASP1/ACE/MMP3/MMP1/JAK1 |
15 |
| hsa05235 |
PD-L1 expression and PD-1 checkpoint pathway in cancer |
11/47 |
90/8859 |
8.21E-13 |
6.89E-12 |
1.76E-12 |
AKT1/EGFR/MAPK3/STAT1/MAPK1/PIK3CA/HRAS/JAK2/MAPK14/LCK/JAK1 |
11 |
| hsa04926 |
Relaxin signaling pathway |
12/47 |
130/8859 |
2.02E-12 |
1.63E-11 |
4.16E-12 |
AKT1/EGFR/SRC/MMP9/MAPK3/MAPK1/PIK3CA/HRAS/MAPK8/MAPK14/NOS3/MMP1 |
12 |
| hsa05164 |
Influenza A |
13/47 |
173/8859 |
3.02E-12 |
2.32E-11 |
5.94E-12 |
TNF/IL6/AKT1/CASP3/MAPK3/STAT1/MAPK1/PIK3CA/JAK2/CCL5/CASP1/CASP8/JAK1 |
13 |
| hsa05218 |
Melanoma |
10/47 |
73/8859 |
3.10E-12 |
2.32E-11 |
5.94E-12 |
AKT1/EGFR/MAPK3/IGF1/MAPK1/PIK3CA/HRAS/MDM2/HGF/IGF1R |
10 |
| hsa05142 |
Chagas disease |
11/47 |
103/8859 |
3.75E-12 |
2.71E-11 |
6.94E-12 |
TNF/IL6/AKT1/MAPK3/MAPK1/PIK3CA/CCL5/MAPK8/MAPK14/CASP8/ACE |
11 |
| hsa05418 |
Fluid shear stress and atherosclerosis |
12/47 |
141/8859 |
5.35E-12 |
3.74E-11 |
9.57E-12 |
TNF/AKT1/SRC/MMP9/KDR/RHOA/PIK3CA/MAPK8/MAPK14/HMOX1/NOS3/SELE |
12 |
| hsa05133 |
Pertussis |
10/47 |
78/8859 |
6.16E-12 |
4.17E-11 |
1.07E-11 |
TNF/IL6/CASP3/MAPK3/MAPK1/RHOA/ITGB1/MAPK8/MAPK14/CASP1 |
10 |
| hsa04621 |
NOD-like receptor signaling pathway |
13/47 |
189/8859 |
9.36E-12 |
6.14E-11 |
1.57E-11 |
TNF/IL6/MAPK3/STAT1/MAPK1/RHOA/CCL5/MAPK8/MAPK14/CASP1/CASP8/CTSB/JAK1 |
13 |
| hsa04014 |
Ras signaling pathway |
14/47 |
238/8859 |
1.08E-11 |
6.89E-11 |
1.76E-11 |
AKT1/EGFR/MAPK3/IGF1/KDR/MAPK1/RHOA/PIK3CA/KIT/HRAS/HGF/MAPK8/IGF1R/FLT1 |
14 |
| hsa04010 |
MAPK signaling pathway |
15/47 |
300/8859 |
1.76E-11 |
1.09E-10 |
2.79E-11 |
TNF/AKT1/EGFR/CASP3/MAPK3/IGF1/KDR/MAPK1/KIT/HRAS/HGF/MAPK8/IGF1R/MAPK14/FLT1 |
15 |
| hsa05131 |
Shigellosis |
14/47 |
250/8859 |
2.11E-11 |
1.26E-10 |
3.23E-11 |
TNF/AKT1/EGFR/SRC/MAPK3/MAPK1/RHOA/PIK3CA/ITGB1/CCL5/MDM2/MAPK8/MAPK14/CASP1 |
14 |
| hsa05132 |
Salmonella infection |
14/47 |
251/8859 |
2.22E-11 |
1.27E-10 |
3.25E-11 |
TNF/IL6/GAPDH/AKT1/CASP3/MAPK3/MAPK1/RHOA/PIK3CA/HRAS/MAPK8/MAPK14/CASP1/CASP8 |
14 |
| hsa05160 |
Hepatitis C |
12/47 |
159/8859 |
2.24E-11 |
1.27E-10 |
3.25E-11 |
TNF/AKT1/EGFR/CASP3/MAPK3/STAT1/MAPK1/PIK3CA/HRAS/CASP8/CDK2/JAK1 |
12 |
| hsa05130 |
Pathogenic Escherichia coli infection |
13/47 |
203/8859 |
2.32E-11 |
1.28E-10 |
3.28E-11 |
TNF/IL6/GAPDH/SRC/CASP3/MAPK3/MAPK1/RHOA/ITGB1/MAPK8/MAPK14/CASP1/CASP8 |
13 |
| hsa05169 |
Epstein-Barr virus infection |
13/47 |
204/8859 |
2.47E-11 |
1.33E-10 |
3.40E-11 |
TNF/IL6/AKT1/CASP3/STAT1/PIK3CA/MDM2/MAPK8/MAPK14/SYK/CASP8/CDK2/JAK1 |
13 |
| hsa05219 |
Bladder cancer |
8/47 |
41/8859 |
2.81E-11 |
1.48E-10 |
3.78E-11 |
EGFR/SRC/MMP9/MAPK3/MAPK1/HRAS/MDM2/MMP1 |
8 |
| hsa04664 |
Fc epsilon RI signaling pathway |
9/47 |
69/8859 |
6.63E-11 |
3.40E-10 |
8.69E-11 |
TNF/AKT1/MAPK3/MAPK1/PIK3CA/HRAS/MAPK8/MAPK14/SYK |
9 |
| hsa05165 |
Human papillomavirus infection |
15/47 |
333/8859 |
7.79E-11 |
3.90E-10 |
9.96E-11 |
TNF/AKT1/EGFR/CASP3/MAPK3/PTGS2/STAT1/MAPK1/PIK3CA/HRAS/ITGB1/MDM2/CASP8/CDK2/JAK1 |
15 |
| hsa04915 |
Estrogen signaling pathway |
11/47 |
139/8859 |
1.02E-10 |
5.00E-10 |
1.28E-10 |
AKT1/EGFR/SRC/MMP9/MAPK3/ESR1/MAPK1/PIK3CA/HRAS/PGR/NOS3 |
11 |
| hsa04380 |
Osteoclast differentiation |
11/47 |
143/8859 |
1.39E-10 |
6.66E-10 |
1.70E-10 |
TNF/AKT1/MAPK3/STAT1/MAPK1/PIK3CA/MAPK8/MAPK14/SYK/LCK/JAK1 |
11 |
| hsa05214 |
Glioma |
9/47 |
76/8859 |
1.62E-10 |
7.57E-10 |
1.94E-10 |
AKT1/EGFR/MAPK3/IGF1/MAPK1/PIK3CA/HRAS/MDM2/IGF1R |
9 |
| hsa05224 |
Breast cancer |
11/47 |
148/8859 |
2.03E-10 |
9.25E-10 |
2.36E-10 |
AKT1/EGFR/MAPK3/IGF1/ESR1/MAPK1/PIK3CA/KIT/HRAS/IGF1R/PGR |
11 |
| hsa04914 |
Progesterone-mediated oocyte maturation |
10/47 |
111/8859 |
2.22E-10 |
9.93E-10 |
2.54E-10 |
AKT1/MAPK3/IGF1/MAPK1/PIK3CA/MAPK8/IGF1R/MAPK14/PGR/CDK2 |
10 |
| hsa05140 |
Leishmaniasis |
9/47 |
79/8859 |
2.32E-10 |
1.01E-09 |
2.59E-10 |
TNF/MAPK3/PTGS2/STAT1/MAPK1/JAK2/ITGB1/MAPK14/JAK1 |
9 |
| hsa05203 |
Viral carcinogenesis |
12/47 |
205/8859 |
4.39E-10 |
1.88E-09 |
4.81E-10 |
SRC/CASP3/MAPK3/MAPK1/RHOA/PIK3CA/HRAS/MDM2/SYK/CASP8/CDK2/JAK1 |
12 |
| hsa05210 |
Colorectal cancer |
9/47 |
87/8859 |
5.60E-10 |
2.26E-09 |
5.77E-10 |
AKT1/EGFR/CASP3/MAPK3/MAPK1/RHOA/PIK3CA/HRAS/MAPK8 |
9 |
| hsa04071 |
Sphingolipid signaling pathway |
10/47 |
122/8859 |
5.70E-10 |
2.26E-09 |
5.77E-10 |
TNF/AKT1/MAPK3/MAPK1/RHOA/PIK3CA/HRAS/MAPK8/MAPK14/NOS3 |
10 |
| hsa04660 |
T cell receptor signaling pathway |
10/47 |
122/8859 |
5.70E-10 |
2.26E-09 |
5.77E-10 |
TNF/AKT1/MAPK3/MAPK1/RHOA/PIK3CA/HRAS/MAPK8/MAPK14/LCK |
10 |
| hsa04935 |
Growth hormone synthesis, secretion and action |
10/47 |
122/8859 |
5.70E-10 |
2.26E-09 |
5.77E-10 |
AKT1/MAPK3/IGF1/STAT1/MAPK1/PIK3CA/HRAS/JAK2/MAPK8/MAPK14 |
10 |
| hsa04611 |
Platelet activation |
10/47 |
126/8859 |
7.84E-10 |
3.05E-09 |
7.80E-10 |
AKT1/SRC/MAPK3/MAPK1/RHOA/PIK3CA/ITGB1/MAPK14/SYK/NOS3 |
10 |
| hsa04210 |
Apoptosis |
10/47 |
136/8859 |
1.67E-09 |
6.36E-09 |
1.63E-09 |
TNF/AKT1/CASP3/MAPK3/MAPK1/PIK3CA/HRAS/MAPK8/CASP8/CTSB |
10 |
| hsa04550 |
Signaling pathways regulating pluripotency of stem cells |
10/47 |
144/8859 |
2.92E-09 |
1.09E-08 |
2.79E-09 |
AKT1/MAPK3/IGF1/MAPK1/PIK3CA/HRAS/JAK2/IGF1R/MAPK14/JAK1 |
10 |
| hsa04659 |
Th17 cell differentiation |
9/47 |
109/8859 |
4.27E-09 |
1.57E-08 |
4.02E-09 |
IL6/MAPK3/STAT1/MAPK1/JAK2/MAPK8/MAPK14/LCK/JAK1 |
9 |
| hsa05206 |
MicroRNAs in cancer |
13/47 |
312/8859 |
4.78E-09 |
1.73E-08 |
4.43E-09 |
EGFR/MMP9/CASP3/MAPK3/PTGS2/MAPK1/RHOA/PIK3CA/HRAS/MDM2/SIRT1/HMOX1/PLAU |
13 |
| hsa05212 |
Pancreatic cancer |
8/47 |
77/8859 |
5.38E-09 |
1.91E-08 |
4.89E-09 |
AKT1/EGFR/MAPK3/STAT1/MAPK1/PIK3CA/MAPK8/JAK1 |
8 |
| hsa04218 |
Cellular senescence |
10/47 |
157/8859 |
6.76E-09 |
2.37E-08 |
6.05E-09 |
IL6/AKT1/MAPK3/MAPK1/PIK3CA/HRAS/MDM2/SIRT1/MAPK14/CDK2 |
10 |
| hsa05207 |
Chemical carcinogenesis - receptor activation |
11/47 |
215/8859 |
1.08E-08 |
3.71E-08 |
9.49E-09 |
AKT1/EGFR/SRC/MAPK3/ESR1/MAPK1/PIK3CA/HRAS/JAK2/PGR/AR |
11 |
| hsa04919 |
Thyroid hormone signaling pathway |
9/47 |
122/8859 |
1.16E-08 |
3.93E-08 |
1.01E-08 |
AKT1/SRC/MAPK3/ESR1/STAT1/MAPK1/PIK3CA/HRAS/MDM2 |
9 |
| hsa04012 |
ErbB signaling pathway |
8/47 |
86/8859 |
1.31E-08 |
4.36E-08 |
1.12E-08 |
AKT1/EGFR/SRC/MAPK3/MAPK1/PIK3CA/HRAS/MAPK8 |
8 |
| hsa05166 |
Human T-cell leukemia virus 1 infection |
11/47 |
224/8859 |
1.65E-08 |
5.42E-08 |
1.39E-08 |
TNF/IL6/AKT1/MAPK3/MAPK1/PIK3CA/HRAS/MAPK8/LCK/CDK2/JAK1 |
11 |
| hsa05208 |
Chemical carcinogenesis - reactive oxygen species |
11/47 |
226/8859 |
1.81E-08 |
5.86E-08 |
1.50E-08 |
AKT1/EGFR/SRC/MAPK3/MAPK1/PIK3CA/HRAS/HGF/MAPK8/MAPK14/HMOX1 |
11 |
| hsa04658 |
Th1 and Th2 cell differentiation |
8/47 |
93/8859 |
2.44E-08 |
7.78E-08 |
1.99E-08 |
MAPK3/STAT1/MAPK1/JAK2/MAPK8/MAPK14/LCK/JAK1 |
8 |
| hsa05162 |
Measles |
9/47 |
139/8859 |
3.65E-08 |
1.14E-07 |
2.93E-08 |
IL6/AKT1/CASP3/STAT1/PIK3CA/MAPK8/CASP8/CDK2/JAK1 |
9 |
| hsa04062 |
Chemokine signaling pathway |
10/47 |
193/8859 |
4.90E-08 |
1.51E-07 |
3.87E-08 |
AKT1/SRC/MAPK3/STAT1/MAPK1/RHOA/PIK3CA/HRAS/JAK2/CCL5 |
10 |
| hsa05221 |
Acute myeloid leukemia |
7/47 |
68/8859 |
5.65E-08 |
1.72E-07 |
4.39E-08 |
AKT1/MAPK3/MAPK1/PIK3CA/KIT/HRAS/MPO |
7 |
| hsa04072 |
Phospholipase D signaling pathway |
9/47 |
149/8859 |
6.68E-08 |
2.00E-07 |
5.12E-08 |
AKT1/EGFR/MAPK3/MAPK1/RHOA/PIK3CA/KIT/HRAS/SYK |
9 |
| hsa05230 |
Central carbon metabolism in cancer |
7/47 |
71/8859 |
7.65E-08 |
2.26E-07 |
5.79E-08 |
AKT1/EGFR/MAPK3/MAPK1/PIK3CA/KIT/HRAS |
7 |
| hsa05223 |
Non-small cell lung cancer |
7/47 |
73/8859 |
9.30E-08 |
2.71E-07 |
6.94E-08 |
AKT1/EGFR/MAPK3/MAPK1/PIK3CA/HRAS/HGF |
7 |
| hsa04150 |
mTOR signaling pathway |
9/47 |
158/8859 |
1.11E-07 |
3.19E-07 |
8.16E-08 |
TNF/AKT1/MAPK3/IGF1/MAPK1/RHOA/PIK3CA/HRAS/IGF1R |
9 |
| hsa01524 |
Platinum drug resistance |
7/47 |
75/8859 |
1.12E-07 |
3.19E-07 |
8.16E-08 |
AKT1/CASP3/MAPK3/MAPK1/PIK3CA/MDM2/CASP8 |
7 |
| hsa05170 |
Human immunodeficiency virus 1 infection |
10/47 |
213/8859 |
1.24E-07 |
3.48E-07 |
8.91E-08 |
TNF/AKT1/CASP3/MAPK3/MAPK1/PIK3CA/HRAS/MAPK8/MAPK14/CASP8 |
10 |
| hsa04722 |
Neurotrophin signaling pathway |
8/47 |
120/8859 |
1.81E-07 |
5.01E-07 |
1.28E-07 |
AKT1/MAPK3/MAPK1/RHOA/PIK3CA/HRAS/MAPK8/MAPK14 |
8 |
| hsa05225 |
Hepatocellular carcinoma |
9/47 |
170/8859 |
2.08E-07 |
5.67E-07 |
1.45E-07 |
AKT1/EGFR/MAPK3/MAPK1/PIK3CA/HRAS/HGF/IGF1R/HMOX1 |
9 |
| hsa04650 |
Natural killer cell mediated cytotoxicity |
8/47 |
136/8859 |
4.77E-07 |
1.28E-06 |
3.28E-07 |
TNF/CASP3/MAPK3/MAPK1/PIK3CA/HRAS/SYK/LCK |
8 |
| hsa04912 |
GnRH signaling pathway |
7/47 |
93/8859 |
5.00E-07 |
1.33E-06 |
3.40E-07 |
EGFR/SRC/MAPK3/MAPK1/HRAS/MAPK8/MAPK14 |
7 |
| hsa04114 |
Oocyte meiosis |
8/47 |
139/8859 |
5.63E-07 |
1.48E-06 |
3.78E-07 |
MAPK3/IGF1/MAPK1/IGF1R/MAPK14/PGR/CDK2/AR |
8 |
| hsa05213 |
Endometrial cancer |
6/47 |
59/8859 |
5.85E-07 |
1.52E-06 |
3.87E-07 |
AKT1/EGFR/MAPK3/MAPK1/PIK3CA/HRAS |
6 |
| hsa05010 |
Alzheimer disease |
12/47 |
391/8859 |
5.93E-07 |
1.52E-06 |
3.88E-07 |
TNF/IL6/GAPDH/AKT1/CASP3/MAPK3/PTGS2/MAPK1/PIK3CA/HRAS/MAPK8/CASP8 |
12 |
| hsa04613 |
Neutrophil extracellular trap formation |
9/47 |
193/8859 |
6.11E-07 |
1.53E-06 |
3.91E-07 |
AKT1/SRC/MAPK3/MAPK1/PIK3CA/MPO/MAPK14/SYK/CASP1 |
9 |
| hsa05202 |
Transcriptional misregulation in cancer |
9/47 |
193/8859 |
6.11E-07 |
1.53E-06 |
3.91E-07 |
IL6/MMP9/IGF1/MDM2/IGF1R/MPO/MMP3/FLT1/PLAU |
9 |
| hsa04936 |
Alcoholic liver disease |
8/47 |
144/8859 |
7.38E-07 |
1.82E-06 |
4.66E-07 |
TNF/IL6/AKT1/CASP3/MAPK8/SIRT1/MAPK14/CASP8 |
8 |
| hsa05231 |
Choline metabolism in cancer |
7/47 |
99/8859 |
7.67E-07 |
1.87E-06 |
4.79E-07 |
AKT1/EGFR/MAPK3/MAPK1/PIK3CA/HRAS/MAPK8 |
7 |
| hsa04213 |
Longevity regulating pathway - multiple species |
6/47 |
62/8859 |
7.88E-07 |
1.90E-06 |
4.86E-07 |
AKT1/IGF1/PIK3CA/HRAS/SIRT1/IGF1R |
6 |
| hsa05226 |
Gastric cancer |
8/47 |
150/8859 |
1.01E-06 |
2.40E-06 |
6.15E-07 |
AKT1/EGFR/MAPK3/MAPK1/PIK3CA/HRAS/HGF/CDK2 |
8 |
| hsa04921 |
Oxytocin signaling pathway |
8/47 |
155/8859 |
1.29E-06 |
3.05E-06 |
7.79E-07 |
EGFR/SRC/MAPK3/PTGS2/MAPK1/RHOA/HRAS/NOS3 |
8 |
| hsa04148 |
Efferocytosis |
8/47 |
157/8859 |
1.42E-06 |
3.29E-06 |
8.40E-07 |
CASP3/MAPK3/PTGS2/MAPK1/JAK2/SIRT1/MAPK14/CASP1 |
8 |
| hsa04932 |
Non-alcoholic fatty liver disease |
8/47 |
157/8859 |
1.42E-06 |
3.29E-06 |
8.40E-07 |
TNF/IL6/AKT1/CASP3/PIK3CA/MAPK8/MAPK14/CASP8 |
8 |
| hsa05211 |
Renal cell carcinoma |
6/47 |
70/8859 |
1.63E-06 |
3.72E-06 |
9.50E-07 |
AKT1/MAPK3/MAPK1/PIK3CA/HRAS/HGF |
6 |
| hsa05120 |
Epithelial cell signaling in Helicobacter pylori infection |
6/47 |
71/8859 |
1.77E-06 |
4.00E-06 |
1.02E-06 |
EGFR/SRC/CASP3/CCL5/MAPK8/MAPK14 |
6 |
| hsa04630 |
JAK-STAT signaling pathway |
8/47 |
168/8859 |
2.37E-06 |
5.30E-06 |
1.35E-06 |
IL6/AKT1/EGFR/STAT1/PIK3CA/HRAS/JAK2/JAK1 |
8 |
| hsa04140 |
Autophagy - animal |
8/47 |
169/8859 |
2.48E-06 |
5.48E-06 |
1.40E-06 |
AKT1/MAPK3/MAPK1/PIK3CA/HRAS/MAPK8/IGF1R/CTSB |
8 |
| hsa04810 |
Regulation of actin cytoskeleton |
9/47 |
230/8859 |
2.64E-06 |
5.78E-06 |
1.48E-06 |
AKT1/EGFR/SRC/MAPK3/MAPK1/RHOA/PIK3CA/HRAS/ITGB1 |
9 |
| hsa05220 |
Chronic myeloid leukemia |
6/47 |
77/8859 |
2.86E-06 |
6.20E-06 |
1.58E-06 |
AKT1/MAPK3/MAPK1/PIK3CA/HRAS/MDM2 |
6 |
| hsa04930 |
Type II diabetes mellitus |
5/47 |
47/8859 |
4.39E-06 |
9.40E-06 |
2.40E-06 |
TNF/MAPK3/MAPK1/PIK3CA/MAPK8 |
5 |
| hsa04211 |
Longevity regulating pathway |
6/47 |
90/8859 |
7.14E-06 |
1.51E-05 |
3.87E-06 |
AKT1/IGF1/PIK3CA/HRAS/SIRT1/IGF1R |
6 |
| hsa04662 |
B cell receptor signaling pathway |
6/47 |
91/8859 |
7.61E-06 |
1.60E-05 |
4.09E-06 |
AKT1/MAPK3/MAPK1/PIK3CA/HRAS/SYK |
6 |
| hsa04520 |
Adherens junction |
6/47 |
93/8859 |
8.64E-06 |
1.78E-05 |
4.55E-06 |
EGFR/SRC/MAPK3/MAPK1/RHOA/IGF1R |
6 |
| hsa05222 |
Small cell lung cancer |
6/47 |
93/8859 |
8.64E-06 |
1.78E-05 |
4.55E-06 |
AKT1/CASP3/PTGS2/PIK3CA/ITGB1/CDK2 |
6 |
| hsa05323 |
Rheumatoid arthritis |
6/47 |
95/8859 |
9.77E-06 |
1.99E-05 |
5.09E-06 |
TNF/IL6/CCL5/MMP3/MMP1/FLT1 |
6 |
| hsa05415 |
Diabetic cardiomyopathy |
8/47 |
205/8859 |
1.04E-05 |
2.10E-05 |
5.36E-06 |
GAPDH/AKT1/MMP9/PIK3CA/MAPK8/MAPK14/ACE/NOS3 |
8 |
| hsa05134 |
Legionellosis |
5/47 |
56/8859 |
1.05E-05 |
2.11E-05 |
5.39E-06 |
TNF/IL6/CASP3/CASP1/CASP8 |
5 |
| hsa05020 |
Prion disease |
9/47 |
278/8859 |
1.24E-05 |
2.46E-05 |
6.28E-06 |
TNF/IL6/CASP3/MAPK3/MAPK1/PIK3CA/CCL5/MAPK8/MAPK14 |
9 |
| hsa04730 |
Long-term depression |
5/47 |
60/8859 |
1.48E-05 |
2.91E-05 |
7.44E-06 |
MAPK3/IGF1/MAPK1/HRAS/IGF1R |
5 |
| hsa04217 |
Necroptosis |
7/47 |
159/8859 |
1.81E-05 |
3.52E-05 |
8.99E-06 |
TNF/STAT1/JAK2/MAPK8/CASP1/CASP8/JAK1 |
7 |
| hsa04931 |
Insulin resistance |
6/47 |
109/8859 |
2.15E-05 |
4.15E-05 |
1.06E-05 |
TNF/IL6/AKT1/PIK3CA/MAPK8/NOS3 |
6 |
| hsa04929 |
GnRH secretion |
5/47 |
65/8859 |
2.20E-05 |
4.20E-05 |
1.07E-05 |
AKT1/MAPK3/MAPK1/PIK3CA/HRAS |
5 |
| hsa04725 |
Cholinergic synapse |
6/47 |
116/8859 |
3.07E-05 |
5.80E-05 |
1.48E-05 |
AKT1/MAPK3/MAPK1/PIK3CA/HRAS/JAK2 |
6 |
| hsa04115 |
p53 signaling pathway |
5/47 |
75/8859 |
4.42E-05 |
8.28E-05 |
2.12E-05 |
CASP3/IGF1/MDM2/CASP8/CDK2 |
5 |
| hsa04960 |
Aldosterone-regulated sodium reabsorption |
4/47 |
38/8859 |
4.50E-05 |
8.36E-05 |
2.14E-05 |
MAPK3/IGF1/MAPK1/PIK3CA |
4 |
| hsa04360 |
Axon guidance |
7/47 |
184/8859 |
4.63E-05 |
8.54E-05 |
2.18E-05 |
SRC/MAPK3/MAPK1/RHOA/PIK3CA/HRAS/ITGB1 |
7 |
| hsa04623 |
Cytosolic DNA-sensing pathway |
5/47 |
83/8859 |
7.20E-05 |
0.0001315 |
3.36E-05 |
IL6/CASP3/CCL5/CASP1/CASP8 |
5 |
| hsa04910 |
Insulin signaling pathway |
6/47 |
138/8859 |
8.14E-05 |
0.0001473 |
3.77E-05 |
AKT1/MAPK3/MAPK1/PIK3CA/HRAS/MAPK8 |
6 |
| hsa04540 |
Gap junction |
5/47 |
92/8859 |
0.0001177 |
0.0002113 |
5.40E-05 |
EGFR/SRC/MAPK3/MAPK1/HRAS |
5 |
| hsa05144 |
Malaria |
4/47 |
50/8859 |
0.0001339 |
0.0002384 |
6.09E-05 |
TNF/IL6/HGF/SELE |
4 |
| hsa04666 |
Fc gamma R-mediated phagocytosis |
5/47 |
99/8859 |
0.0001665 |
0.000289 |
7.39E-05 |
AKT1/MAPK3/MAPK1/PIK3CA/SYK |
5 |
| hsa04750 |
Inflammatory mediator regulation of TRP channels |
5/47 |
99/8859 |
0.0001665 |
0.000289 |
7.39E-05 |
SRC/IGF1/PIK3CA/MAPK8/MAPK14 |
5 |
| hsa05410 |
Hypertrophic cardiomyopathy |
5/47 |
99/8859 |
0.0001665 |
0.000289 |
7.39E-05 |
TNF/IL6/IGF1/ITGB1/ACE |
5 |
| hsa05022 |
Pathways of neurodegeneration - multiple diseases |
10/47 |
483/8859 |
0.0001763 |
0.0003034 |
7.76E-05 |
TNF/IL6/CASP3/MAPK3/PTGS2/MAPK1/HRAS/MAPK8/MAPK14/CASP8 |
10 |
| hsa04064 |
NF-kappa B signaling pathway |
5/47 |
105/8859 |
0.0002195 |
0.0003748 |
9.58E-05 |
TNF/PTGS2/SYK/LCK/PLAU |
5 |
| hsa04726 |
Serotonergic synapse |
5/47 |
115/8859 |
0.0003354 |
0.0005681 |
0.0001452 |
CASP3/MAPK3/PTGS2/MAPK1/HRAS |
5 |
| hsa04670 |
Leukocyte transendothelial migration |
5/47 |
116/8859 |
0.0003492 |
0.0005866 |
0.00015 |
MMP9/RHOA/PIK3CA/ITGB1/MAPK14 |
5 |
| hsa04152 |
AMPK signaling pathway |
5/47 |
122/8859 |
0.0004407 |
0.0007345 |
0.0001878 |
AKT1/IGF1/PIK3CA/SIRT1/IGF1R |
5 |
| hsa04920 |
Adipocytokine signaling pathway |
4/47 |
70/8859 |
0.0004935 |
0.000816 |
0.0002086 |
TNF/AKT1/JAK2/MAPK8 |
4 |
| hsa04622 |
RIG-I-like receptor signaling pathway |
4/47 |
72/8859 |
0.0005495 |
0.0009015 |
0.0002304 |
TNF/MAPK8/MAPK14/CASP8 |
4 |
| hsa04215 |
Apoptosis - multiple species |
3/47 |
32/8859 |
0.0006232 |
0.0010145 |
0.0002594 |
CASP3/MAPK8/CASP8 |
3 |
| hsa05100 |
Bacterial invasion of epithelial cells |
4/47 |
78/8859 |
0.0007443 |
0.0012024 |
0.0003074 |
SRC/RHOA/PIK3CA/ITGB1 |
4 |
| hsa04371 |
Apelin signaling pathway |
5/47 |
140/8859 |
0.0008256 |
0.0013235 |
0.0003383 |
AKT1/MAPK3/MAPK1/HRAS/NOS3 |
5 |
| hsa05143 |
African trypanosomiasis |
3/47 |
37/8859 |
0.0009583 |
0.0015131 |
0.0003868 |
TNF/IL6/SELE |
3 |
| hsa05216 |
Thyroid cancer |
3/47 |
37/8859 |
0.0009583 |
0.0015131 |
0.0003868 |
MAPK3/MAPK1/HRAS |
3 |
| hsa04723 |
Retrograde endocannabinoid signaling |
5/47 |
149/8859 |
0.0010929 |
0.0017127 |
0.0004378 |
MAPK3/PTGS2/MAPK1/MAPK8/MAPK14 |
5 |
| hsa04024 |
cAMP signaling pathway |
6/47 |
226/8859 |
0.0011548 |
0.0017964 |
0.0004592 |
AKT1/MAPK3/MAPK1/RHOA/PIK3CA/MAPK8 |
6 |
| hsa04022 |
cGMP-PKG signaling pathway |
5/47 |
166/8859 |
0.0017664 |
0.0027276 |
0.0006973 |
AKT1/MAPK3/MAPK1/RHOA/NOS3 |
5 |
| hsa04916 |
Melanogenesis |
4/47 |
101/8859 |
0.0019492 |
0.0029879 |
0.0007638 |
MAPK3/MAPK1/KIT/HRAS |
4 |
| hsa04144 |
Endocytosis |
6/47 |
252/8859 |
0.0020152 |
0.0030667 |
0.000784 |
EGFR/SRC/RHOA/HRAS/MDM2/IGF1R |
6 |
| hsa05146 |
Amoebiasis |
4/47 |
103/8859 |
0.0020945 |
0.0031644 |
0.0008089 |
TNF/IL6/CASP3/PIK3CA |
4 |
| hsa04913 |
Ovarian steroidogenesis |
3/47 |
51/8859 |
0.0024385 |
0.0036577 |
0.0009351 |
PTGS2/IGF1/IGF1R |
3 |
| hsa04350 |
TGF-beta signaling pathway |
4/47 |
108/8859 |
0.0024903 |
0.0037089 |
0.0009481 |
TNF/MAPK3/MAPK1/RHOA |
4 |
| hsa04928 |
Parathyroid hormone synthesis, secretion and action |
4/47 |
115/8859 |
0.0031269 |
0.0046242 |
0.0011821 |
EGFR/MAPK3/MAPK1/RHOA |
4 |
| hsa04923 |
Regulation of lipolysis in adipocytes |
3/47 |
59/8859 |
0.0036956 |
0.0054271 |
0.0013874 |
AKT1/PTGS2/PIK3CA |
3 |
| hsa05321 |
Inflammatory bowel disease |
3/47 |
66/8859 |
0.0050691 |
0.0073924 |
0.0018898 |
TNF/IL6/STAT1 |
3 |
| hsa04720 |
Long-term potentiation |
3/47 |
67/8859 |
0.0052871 |
0.0076572 |
0.0019575 |
MAPK3/MAPK1/HRAS |
3 |
| hsa04261 |
Adrenergic signaling in cardiomyocytes |
4/47 |
154/8859 |
0.0087704 |
0.0126149 |
0.0032249 |
AKT1/MAPK3/MAPK1/MAPK14 |
4 |
| hsa04934 |
Cushing syndrome |
4/47 |
155/8859 |
0.0089682 |
0.0128117 |
0.0032752 |
EGFR/MAPK3/MAPK1/CDK2 |
4 |
| hsa04020 |
Calcium signaling pathway |
5/47 |
254/8859 |
0.0107032 |
0.015187 |
0.0038824 |
EGFR/KDR/HGF/NOS3/FLT1 |
5 |
| hsa01523 |
Antifolate resistance |
2/47 |
30/8859 |
0.0109033 |
0.0153671 |
0.0039284 |
TNF/IL6 |
2 |
| hsa04530 |
Tight junction |
4/47 |
170/8859 |
0.0122931 |
0.0172104 |
0.0043996 |
SRC/RHOA/ITGB1/MAPK8 |
4 |
| hsa04061 |
Viral protein interaction with cytokine and cytokine receptor |
3/47 |
100/8859 |
0.0158044 |
0.0218351 |
0.0055819 |
TNF/IL6/CCL5 |
3 |
| hsa04640 |
Hematopoietic cell lineage |
3/47 |
100/8859 |
0.0158044 |
0.0218351 |
0.0055819 |
TNF/IL6/KIT |
3 |
| hsa04137 |
Mitophagy - animal |
3/47 |
105/8859 |
0.0179892 |
0.0245307 |
0.006271 |
SRC/HRAS/MAPK8 |
3 |
| hsa05414 |
Dilated cardiomyopathy |
3/47 |
105/8859 |
0.0179892 |
0.0245307 |
0.006271 |
TNF/IGF1/ITGB1 |
3 |
| hsa05332 |
Graft-versus-host disease |
2/47 |
45/8859 |
0.0235978 |
0.0319712 |
0.0081731 |
TNF/IL6 |
2 |
| hsa04973 |
Carbohydrate digestion and absorption |
2/47 |
52/8859 |
0.0308767 |
0.0415648 |
0.0106256 |
AKT1/PIK3CA |
2 |
| hsa04728 |
Dopaminergic synapse |
3/47 |
132/8859 |
0.0325729 |
0.0435688 |
0.0111379 |
AKT1/MAPK8/MAPK14 |
3 |
| hsa04270 |
Vascular smooth muscle contraction |
3/47 |
134/8859 |
0.03384 |
0.0449773 |
0.0114979 |
MAPK3/MAPK1/RHOA |
3 |
|